Bimetallic Pt-based catalysts have been extensively investigated to enhance the performance of direct methanol fuel cells(DMFCs) because CO, a by-product, reduces the activity of the pure Pt catalysts. Herein, we synt...Bimetallic Pt-based catalysts have been extensively investigated to enhance the performance of direct methanol fuel cells(DMFCs) because CO, a by-product, reduces the activity of the pure Pt catalysts. Herein, we synthesized Pt-Pb hexagonal nanoplates as a model catalyst for the methanol oxidation reaction(MOR) and further controlled the Pt and Pb distributions on the surface of the nanoplates through acetic acid(HAc) treatment. As a result, we obtained Pt-Pb nanoplates and HAc-treated Pt-Pb nanoplates with homogeneous and heterogeneous distributions of the Pt-Pb alloy surfaces, respectively. We showed that the MOR activity and stability of the Pt-Pb nanoplates improved compared to those of the HAc-treated Pt-Pb nanoplates, mainly due to the enhanced CO tolerance and the modified electronic structure of Pt under the influence of the oxophilic Pb.展开更多
Objective:The aim of this study was to evaluate the response rate,time to progression(TTP),overall survival,and safety of the combination of capecitabine plus oxaliplatin in treatment of advanced gastric cancer(AGC).M...Objective:The aim of this study was to evaluate the response rate,time to progression(TTP),overall survival,and safety of the combination of capecitabine plus oxaliplatin in treatment of advanced gastric cancer(AGC).Methods:All the patients with advanced gastric cancer who were not received any prior chemotherapy or radiotherapy were treated with combination of capecitabine(1250 mg/m2 twice daily,days 1-14) plus oxaliplatin(130 mg/m2 as a 2-h intravenous infusion on day 1) every 3 weeks.Results:Two cases of complete response(CR) and 34 cases of partial response(PR) were confirmed,giving an overall response rate of 52.9%,of the 68 patients with advanced gastric cancer.The median TTP and overall survival for all patients were 7.3 and 11.9 months,respectively.Grade 3 leukopenia,thrombocytopenia,nausea/vomiting,and diarrhea were observed in 3,5,1,and 4 patients,respectively.Yet,no grade 4 toxicity was observed.Conclusion:Capecitabine/ oxaliplatin combination chemotherapy is active in patients with advanced gastric cancer.展开更多
Objective： The aim of this study was to evaluate the recent efficacy and adverse reactions of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Seventeen...Objective： The aim of this study was to evaluate the recent efficacy and adverse reactions of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Seventeen cases of NSCLC treated with paclitaxel liposome and nedaplatin for 2 to 6 cycles, by infusing paclitaxel liposome 135 mg/m^2 for 3 h on d 1 and nedaplatin 80 mg/m^2 as infusion on d2. Results： Among 17 patients being evaluated for response to treatment, 1 achieved complete response （CR）, 4 achieved partial response （PR）, 3 achieved stable disease （SD）, 9 achieved progress disease （PD）. The main adverse reaction was haematological toxicities, especially leukopenia and thrombocytopenia. The non-hae- matological toxicities included nausea, vomiting, mild hepatic dysfunction, alopecia and so on. Conclusion： Paclitaxel lipo- some plus nedaplatin was effective and well tolerated for treating patients with advanced NSCLCo展开更多
To improve the contact between platinum catalyst and titanium substrate, a layer of TiO2 nanotube arrays has been synthesized before depositing Pt nanoflowers by pulse electrodeposition. Dramatic improvements in elect...To improve the contact between platinum catalyst and titanium substrate, a layer of TiO2 nanotube arrays has been synthesized before depositing Pt nanoflowers by pulse electrodeposition. Dramatic improvements in electrocatalytic activity （3x） and stability （60x） for methanol oxidation were found, suggesting promising applications in direct methanol fuel cells. The 3x and 60x improvements persist for Pt/Pd catalysts used to overcome the CO poisoning problem.展开更多
文摘Bimetallic Pt-based catalysts have been extensively investigated to enhance the performance of direct methanol fuel cells(DMFCs) because CO, a by-product, reduces the activity of the pure Pt catalysts. Herein, we synthesized Pt-Pb hexagonal nanoplates as a model catalyst for the methanol oxidation reaction(MOR) and further controlled the Pt and Pb distributions on the surface of the nanoplates through acetic acid(HAc) treatment. As a result, we obtained Pt-Pb nanoplates and HAc-treated Pt-Pb nanoplates with homogeneous and heterogeneous distributions of the Pt-Pb alloy surfaces, respectively. We showed that the MOR activity and stability of the Pt-Pb nanoplates improved compared to those of the HAc-treated Pt-Pb nanoplates, mainly due to the enhanced CO tolerance and the modified electronic structure of Pt under the influence of the oxophilic Pb.
文摘Objective:The aim of this study was to evaluate the response rate,time to progression(TTP),overall survival,and safety of the combination of capecitabine plus oxaliplatin in treatment of advanced gastric cancer(AGC).Methods:All the patients with advanced gastric cancer who were not received any prior chemotherapy or radiotherapy were treated with combination of capecitabine(1250 mg/m2 twice daily,days 1-14) plus oxaliplatin(130 mg/m2 as a 2-h intravenous infusion on day 1) every 3 weeks.Results:Two cases of complete response(CR) and 34 cases of partial response(PR) were confirmed,giving an overall response rate of 52.9%,of the 68 patients with advanced gastric cancer.The median TTP and overall survival for all patients were 7.3 and 11.9 months,respectively.Grade 3 leukopenia,thrombocytopenia,nausea/vomiting,and diarrhea were observed in 3,5,1,and 4 patients,respectively.Yet,no grade 4 toxicity was observed.Conclusion:Capecitabine/ oxaliplatin combination chemotherapy is active in patients with advanced gastric cancer.
文摘Objective： The aim of this study was to evaluate the recent efficacy and adverse reactions of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Seventeen cases of NSCLC treated with paclitaxel liposome and nedaplatin for 2 to 6 cycles, by infusing paclitaxel liposome 135 mg/m^2 for 3 h on d 1 and nedaplatin 80 mg/m^2 as infusion on d2. Results： Among 17 patients being evaluated for response to treatment, 1 achieved complete response （CR）, 4 achieved partial response （PR）, 3 achieved stable disease （SD）, 9 achieved progress disease （PD）. The main adverse reaction was haematological toxicities, especially leukopenia and thrombocytopenia. The non-hae- matological toxicities included nausea, vomiting, mild hepatic dysfunction, alopecia and so on. Conclusion： Paclitaxel lipo- some plus nedaplatin was effective and well tolerated for treating patients with advanced NSCLCo
文摘To improve the contact between platinum catalyst and titanium substrate, a layer of TiO2 nanotube arrays has been synthesized before depositing Pt nanoflowers by pulse electrodeposition. Dramatic improvements in electrocatalytic activity （3x） and stability （60x） for methanol oxidation were found, suggesting promising applications in direct methanol fuel cells. The 3x and 60x improvements persist for Pt/Pd catalysts used to overcome the CO poisoning problem.
